Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Michael D Price as its new executive vice president and chief financial officer, it was reported on Monday.
In the new role, Price will manage financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
Price has over 25 years of experience in the pharmaceutical industry. Prior to joining Akcea, he served as EVP and CFO and was elected to the company's board of directors of Novelion Therapeutics. He has also served as VP and CFO at Noven Pharmaceuticals Inc from 2007 to 2016. From 1992 to 2006, he has worked at Bentley Pharmaceuticals Inc serving as VP, CFO, treasurer and secretary. He was also a member of Bentley's board of directors for nine years.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'